Table 9.

Incidence and severity of histopathological findings following H. erinaceus β-glucan preparation treatment to rats.

		Vehicle control		High-dose (2000 mg/kg/day)
Gender		M	F	M	F
Histopathological findings	S2	(N/N)1
Thyroid
Cyst, ultimobronchial, focal	1	1/12	1/12	0/12	0/12
Necrosis, focal	1	1/12	0/12	0/12	0/12
Lung
Alveolar histocytosis, focal	1	1/12	1/12	1/12	1/12
Haemorrhage, acute, focal	2	0/12	2/12	0/12	0/122
Adrenals
Vacuolar degeneration, cortex, foci	1	1/12	0/12	0/12	0/12
Heart (Aorta)
Focal round cell collection	2	0/12	1/12	0/12	0/12
Harderian glands
FRCC, stromal	1	0/12	1/12	0/121	0/12
Lymph nodes, mandibular
Focal round cell collection	1	0/12	1/12	0/12	1/12
Thymus
Congestion, focal	1–2	1/12	1/12	0/12	0/12
Kidneys
Cyst, medulla, focal	1–2	2/12	0/12	0/12	0/12
Focal round cell collection, cortex	1–2	1/12	0/12	1/12	0/12
Congestion, foci, cortex	1	0/12	0/12	1/12	0/12
Mineralization, tubular lumen, foci	1–2	1/12	2/12	0/12	1/12
Liver
Clear cell, portal zone, focal	1–2	3/12	3/12	1/12	0/12
Necrosis, portal zone, focal	1	2/12	1/12	0/12	0/12
Focal round cell collection, portal zone	1	2/12	1/12	1/12	0/12
Prostate
FiRCC, stromal	1–2	1/12	–	1/12	–
Pancreas
Focal round cell collection	1	1/12	1/12	0/12	0/12
Hyperplasia, acinar cell, foci	1	1/12	0/12	0/12	0/12
Spleen
Hemangioma, focal	1–2	1/12	2/12	0/12	0/12

FRCC – Focal round cells collection; FiRCC – Foci round cells collection.

¹Incidence rate – animal numbers of histopathologic findings / animal numbers of histopathologic examinations (N/N).

²The severity grading scheme: 1. minimal (<10%), 2. mild (10–39%), 3. moderate (40–79%), 4. marked (80–100%).